2011.

• Dec.22.2011

  Leukotriene Receptor Antagonist "Onon® Dry Syrup 10%" has received approval for the additional indication of allergic rhinitis(57 KB)

• Dec.13.2011

  Ono Enters into Drug Discovery Collaboration with Receptos on GPCR Protein Crystal Structure Determination Technology(27 KB)

• Dec.08.2011

  Launch of an Intravenous Antiemetic Selective Neurokinin-1（NK1）Receptor Antagonist，"PROEMEND® Intravenous infusion 150mg"(80 KB)

• Nov.30.2011

  FDA Acceptance of New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.S.(57 KB)

• Nov.14.2011

  Announcement of the results from a Phase 2 study of “ONO-5163/KAI-4169”：a calcium sensing receptor agonist(69 KB)

• Oct.20.2011

  Revisions of Consolidated Financial Forecasts(72 KB)

• Oct.04.2011

  Ono to Enter into License Agreements with Merck KGaA(89 KB)

• Sep.29.2011

  New Drug Application for Carfilzomib in Relapsed and Refractory Multiple Myeloma in the U.Ｓ.(111 KB)

• Sep.29.2011

  Additional Indication Application Filed for a Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting“EMEND® Capsule”for Pediatric Patients Aged 12 and older(63 KB)

• Sep.26.2011

  Approval received for an Intravenous Antiemetic Selective Neurokinin-1（NK₁）Receptor Antagonist，“PROEMEND® Intravenous infusion 150mg”(25 KB)

• Sep.21.2011

  Ono and Bristol-Myers Squibb Enter into Strategic Agreement for Anti-PD-1 Antibody，ONO-4538／BMS-936558，and ORENCIA®（abatacept），Rheumatoid Arthritis Agent(71 KB)

• Sep.16.2011

  Glactiv® has received approval for the additional indication of combination use with insulin(85 KB)

• Sep.15.2011

  Launch of RECALBON® Tablets 50mg/Bonoteo® Tablet 50mg，Once per 4week Oral Osteoporosis Treatment in Japan(93 KB)

• Sep.15.2011

  Ono Enters into License Agreement with KAI Phamaceuticals，Inc．for KAI 4169(25 KB)

• Sep.14.2011

  Launch of Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan(19 KB)

• Sep.14.2011

  Ono Enters into License Agreement with Servier for Ivabradine(23 KB)

• Aug.24.2011

  Helsinn Announced to have Initiated Global Pivotal Phase III Clinical Program to Evaluate Anamorelin (ONO-7643/RC-1291) in Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia(19 KB)

• Jul.19.2011

  Launch of Rivastach® Patch，for the Treatment of Dementia of Alzheimer's Type(120 KB)

• Jul.01.2011

  Approval for Corebeta® for Injection 12.5mg for Improvement of Image Quality in Coronary CT Angiography in Japan(11 KB)

• Jul.01.2011

  Approval for RECALBON® Tablets 50mg/Bonoteo® Tablet 50mg, Once per 4weeks Oral Osteoporosis treatment in Japan(50 KB)

• Jun.27.2011

  Lead Compounds Were Successfully Identified in Ion Channel Drug Discovery Collaboration with Evotec(36 KB)

• Jun.01.2011

  Announcement on Co-development and Co-marketing Agreement for Carpal-tunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue(45 KB)

• May.20.2011

  Approval for Additional Indication Application of Type-2 Diabetes Drug,Glactiv® Tablets-Combination Therapy with Alpha-glucosidase Inhibitors-(14 KB)

• May.11.2011

  Announcement on Introduct of Corporate Officer System，Changes of Members of the Board of Directors and Appointment of Corporate Officers(69 KB)

• May.11.2011

  Announcement on Financial Results for FY2010

• Apr.22.2011

  Approval Received for Rivastach® Patch, for the treatment of Alzheimer's disease(168 KB)

• Apr.06.2011

  Announcement on Cancellation of the Company's Own Shares(97 KB)

• Apr.05.2011

  Launch of Orally Disintegrating Tablet of Staybla® Tablets 0.1mg, a Drug for Overactive Bladder(17 KB)

• Mar.29.2011

  Ono Enters into License Agreement with OncoTherapy for New Therapeutic Cancer Peptide Vaccines(54 KB)

• Mar.25.2011

  Announcement on Results and Completion of Acquisition of the Company’s Own Shares(100 KB)

• Jan.11.2011

  Ono and Galapagos subsidiary BioFocus sign target discovery agreement in the field of autoimmune disease(15 KB)